Uptake and Competition Among Biosimilar Biological Products in the US Medicare Fee-for-Service Population

J Gen Intern Med. 2022 Dec;37(16):4292-4294. doi: 10.1007/s11606-022-07670-7. Epub 2022 Jun 1.

Authors

Steven Kozlowski¹, Natasha Flowers², Andrew Kwist², Sarah K Dutcher³, Michael Wernecke², Jeffrey A Kelman⁴, David J Graham³

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Steven.Kozlowski@fda.hhs.gov.
² Acumen, LLC, Burlingame, CA, USA.
³ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
⁴ Centers for Medicare & Medicaid Services, Washington, DC, USA.

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, P.H.S.
Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

Aged
Biosimilar Pharmaceuticals*
Economic Competition
Fee-for-Service Plans
Humans
Medicare*
United States

Substances

Biosimilar Pharmaceuticals

Grants and funding

NA/FD/FDA HHS/United States